Efficacy, Immunogenicity, Safety, and Tolerability of AADvac1 in Alzheimer Disease
AADvac1 demonstrates robust immunogenicity and an acceptable safety profile in early-phase trials. Cognitive benefits remain inconclusive. Larger, long-term trials are needed to confirm its clinical efficacy and long-term safety in AD.
Authors
- Filipe Virgílio Ribeiro (ORCID: https://orcid.org/0000-0002-1091-6624)
- Marianna Leite (ORCID: https://orcid.org/0000-0001-5816-1438)
- Eryvelton de Souza Franco (ORCID: https://orcid.org/0000-0001-5864-7980)
- Isabelle Rodrigues Menezes
- Emmerson Carlos Franco de Farias (ORCID: https://orcid.org/0000-0001-8627-5694)
- Daniel Gonçalves Quiroga (ORCID: https://orcid.org/0000-0002-5544-4923)
- Maria Bernadete de Sousa Maia
- Luciano Falcão Carneiro Filho
- Andreza Jucelly Severina da Silva (ORCID: https://orcid.org/0000-0002-6835-3254)
- María Säo José Nascimento (ORCID: https://orcid.org/0009-0003-9120-8447)
- Anderson Silva Corin (ORCID: https://orcid.org/0009-0004-1148-7085)
Institutions
- Universidade Federal de Minas Gerais (BR)
- Escola Bahiana de Medicina e Saúde Pública (BR)
- Universidade Federal de Pelotas (BR)
- Universidade Federal de Pernambuco (BR)
- Universidade Federal do Rio Grande do Norte (BR)
- Centro Universitário Barão de Mauá (BR)
- Hospital Santa Marcelina (BR)
- Universidade Federal de Roraima (BR)
- Centro Universitário do Rio Grande do Norte (BR)
Publication Details
- Journal
- Alzheimer Disease & Associated Disorders
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1097/wad.0000000000000686
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16